Yes, today. VANCOUVER, Washington, Feb. 10
Post# of 148183
VANCOUVER, Washington, Feb. 10, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company" , a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., president and chief executive officer, will present a comprehensive overview of upcoming milestones anticipated in 2020 for multiple potential therapeutic indications for leronlimab at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on Tuesday, February 11, 2020 at 12:30 p.m. ET / 9:30 a.m. PT.
Date: Tuesday, February 11, 2020
Time: 12:30 p.m. ET / 9:30 a.m. PT
Access: https://www.wallstreetreporter.com/next-super...onference/
The livestream presentation will be archived for 30 days and participants are encouraged to go to the above-referenced website 10 minutes prior to the start of the presentation. For anyone unable to attend, a video will be posted on CytoDyn’s website approximately 24 hours after the presentation. The conference sponsor provides corporate visibility services to CytoDyn for a fee.